Leerink analyst Mani Foroohar raised the firm’s price target on Regenxbio (RGNX) to $20 from $16 and keeps an Outperform rating on the shares. Ahead of a busy 2026 catalyst path for Regenxbio, the firm is updating its model to reflect a larger Duchenne muscular dystrophy opportunity following clinical/regulatory setbacks by first-mover Sarepata (SRPT) – opening the door for Regenxbio to differentiate on safety in particular and take meaningful share.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- RegenXBio’s Strategic Positioning and Advancements Drive Buy Rating Amid Market Opportunities
- RegenXBio’s Gene Therapy Study for Hunter Syndrome: A Potential Game-Changer
- Regenxbio files $300M mixed securities shelf
- RegenXBio’s Strategic Manufacturing and Commercial Readiness Justifies Buy Rating and $34 Price Target
- RegenXBio’s Strategic Manufacturing Edge and Market Position Justify Buy Rating